Ahmad Masri, MD, MS, discusses a study from ACC.24 examining trends in incidence and outcomes of emergency department visits related to hypertrophic cardiomyopathy from 2006 to 2019.
Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.
Ahmad Masri, MD, MS, provides his perspective on the APOLLO-B data and reacts to the FDA CRDAC 9 to 3 vote in favor of the benefit-risk profile for patisiran in ATTR-CM.